Dr Randall Meisner and colleagues from the USA investigated positron emission tomography activity using 18-fluorodeoxyglucose with nearly simultaneous computerized tomography.
The research team evaluated whether this technique for anatomic accuracy would identify regions of active inflammation in both ulcerative colitis and Crohn's disease.
|Positron emission tomography activity was see in 59% of regions in Crohn‘s|
|Inflammatory Bowel Diseases|
The team collected clinical data in 12 patients experiencing an exacerbation of their inflammatory bowel disease.
Of these, 7 had Crohn's disease and 5 had ulcerative colitis.
A positron emission tomography /computerized tomography scan was performed in all patients.
The team evaluated 20 controls who underwent positron emission tomography/computerized tomography because of solitary pulmonary nodules.
The team graded the small bowel and 4 colon regions with positron emission tomography activity scores assigned to each region.
The scores assigned to each region were based on the amount of fluorodeoxyglucose uptake using the liver as the reference organ.
The researchers found that positron emission tomography activity was seen in 52% of regions.
There was high correlation between positron emission tomography activity and disease activity as determined by colonoscopy, disease activity indices, and radiology.
In patients with Crohn's disease, the team observed positron emission tomography activity in 59% of regions.
Again, there was a correlation of 81% between positron emission tomography activity and clinical disease activity.
The team observed significant positron emission tomography activity in only 2% of regions in the controls.
Dr Meisner's team concluded, "We found that positron emission tomography activity correlated well with active inflammation in both ulcerative colitis and Crohn's disease, suggesting that this may be a noninvasive method of identifying disease activity in patients with inflammatory bowel disease."